HIV-Linked Blood Cancers Strike Younger Patients and Cut Survival, Single-Center Study Finds

People living with HIV carry a markedly elevated risk of cancer, and the nature of that risk has been shifting as antiretroviral therapy transforms the disease into a manageable chronic condition. A new retrospective cohort study from a tertiary academic medical center in the southern United States, published in BMC Infectious Diseases, offers a detailed portrait of how malignancies differ in this population depending on whether they arise in solid organs or in the blood and lymphatic system. The findings underscore a persistent truth: immune dysfunction remains tightly linked to blood cancers, while solid tumors increasingly behave like the age- and lifestyle-driven diseases seen in the general population.

The research team, led by Andrew M. Schwartz, Nour Daoud, Wesley P. Jameson, John A. Vanchiere, and Alexandre E. Malek of Louisiana State University Health Sciences Center Shreveport, with Malek also affiliated with McGovern Medical School at The University of Texas Health Science Center at Houston, analyzed 166 people living with HIV who were diagnosed with cancer at their 407-bed institution between 2019 and 2025. Among the 3,640 HIV-positive patients actively receiving care at the center, 4.6 percent were identified as having both HIV infection and a concurrent malignancy. Using the direct standardization method with the US 2000 Standard Population as reference, the investigators calculated an age-standardized cancer detection proportion of 888.1 per 100,000 patients, with a 95 percent confidence interval spanning 753.0 to 1023.2.

The central comparison pitted hematologic malignancies against solid tumors. Blood cancers, including lymphomas and other lymphoproliferative disorders, struck patients at a significantly younger age than solid malignancies did, with a median age at diagnosis of 41 years versus 51 years, a difference that reached statistical significance at p = 0.002. That fourteen-year gap is not merely demographic trivia; it suggests that the biological pathways driving blood cancers in people with HIV operate through mechanisms distinct from the cumulative mutational burden that characterizes most epithelial tumors.

The clinical picture surrounding each cancer type reinforced that distinction. Patients with hematologic malignancies presented with higher HIV viral loads, lower CD4-positive T-cell counts, and poorer adherence to antiretroviral therapy than patients with solid tumors. In other words, the blood cancers appeared precisely where immune control had slipped the furthest. When the researchers moved from univariate comparisons to multivariate logistic regression, one variable stood out: high HIV viral load remained independently associated with hematologic malignancy, carrying an odds ratio of 4.839 with a 95 percent confidence interval of 1.495 to 17.58. Viral load, a direct readout of how well HIV is suppressed, thus served as the strongest statistical signal separating blood cancers from solid ones.

Survival analysis added a sobering dimension. Kaplan-Meier curves showed a trend toward lower overall survival among patients with hematologic malignancies compared with those bearing solid tumors, with a log-rank p value of 0.056, just shy of conventional significance. However, after adjustment for age in multivariate Cox proportional hazards regression, the difference became clearly significant: patients with blood cancers faced roughly three times the hazard of death, with a hazard ratio of 3.00, a 95 percent confidence interval of 1.35 to 6.66, and a p value of 0.007. The researchers complemented the Cox modeling with restricted mean survival time analysis, a method that quantifies the average survival lost over a defined follow-up period and offers a more intuitive measure of the survival gap than hazard ratios alone.

Beyond the solid-versus-hematologic split, the study took a second analytical angle: stratifying malignancies by viral oncogenesis. Many cancers disproportionately affecting people with HIV are driven by co-infecting viruses. Kaposi sarcoma arises through human herpesvirus 8, also known as Kaposi sarcoma herpesvirus; several non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, are linked to Epstein-Barr virus, detectable through Epstein-Barr encoding region in situ hybridization; and cervical and anogenital cancers are driven by human papillomavirus. Hepatitis B and C viruses contribute to hepatocellular carcinoma. In this framework, virus-driven cancers are those whose development depends on the oncogenic activity of a co-infecting pathogen, while non-virus-driven malignancies arise through other mechanisms.

The virus-driven analysis produced some of the study’s most compelling results. Both high HIV viral load and low CD4-positive T-cell count were independently associated with virus-driven malignancy, and the CD4 association was particularly strong, with an odds ratio of 5.129, a 95 percent confidence interval of 1.709 to 17.153, and a p value of 0.005. This finding aligns with the concept of impaired immune surveillance. CD4-positive T cells coordinate the immune response against virus-infected and transformed cells; when their numbers collapse, the body’s defenses against oncogenic viruses falter, allowing co-infecting pathogens to proliferate and drive malignant transformation. The result provides quantitative support for a mechanism long suspected in HIV-associated cancer biology.

The broader context of these findings lies in the epidemiological transition that has accompanied widespread antiretroviral therapy. In the early AIDS era, Kaposi sarcoma and non-Hodgkin lymphoma dominated the cancer burden of people living with HIV, and these AIDS-defining cancers were the hallmark of profound immunosuppression. As therapy extended lives, non-AIDS-defining cancers began to rise, and the cancer profile of this population started to resemble that of aging, chronically ill adults. The current study captures both sides of this transition within a single cohort: hematologic malignancies still track with immune dysfunction, whereas solid tumors increasingly reflect age- and lifestyle-related factors such as smoking, chronic inflammation, and co-morbidities.

The authors conclude that immune dysfunction remains strongly associated with hematologic malignancies in people living with HIV, while solid tumors are increasingly tied to age and lifestyle. Their secondary analysis stratifying malignancies by viral oncogenesis identified consistent associations between immune dysfunction and virus-driven cancer, further supporting the role of impaired immune surveillance in HIV-associated cancer development. For clinicians, the practical message is twofold: sustained viral suppression and preserved CD4 counts may be among the most effective cancer-prevention tools available for this population, and vigilance for blood cancers is warranted particularly in patients showing signs of immunologic deterioration.

The study also carries limitations inherent to its design. As a single-center retrospective cohort of 166 patients, its findings reflect the demographics and clinical practices of one southern US institution and cannot establish causation between viral load, CD4 count, and cancer type. The confidence intervals around several estimates are wide, reflecting the modest sample size. Nevertheless, the consistency of the immune-dysfunction signal across both the hematologic-versus-solid comparison and the virus-driven stratification strengthens the case that maintaining immune integrity is central to preventing the cancers that continue to burden people living with HIV, even in the antiretroviral therapy era.

Subject of Research: HIV-associated cancer

Article Title: Characteristics of solid versus hematologic malignancies in people living with human immunodeficiency virus

Article References: Schwartz, A. M., Daoud, N., Jameson, W. P., Vanchiere, J. A., & Malek, A. E. (2026). Characteristics of solid versus hematologic malignancies in people living with human immunodeficiency virus. BMC Infectious Diseases, 26(1), Article 1717. https://doi.org/10.1186/s12879-026-14236-z

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14236-z

Keywords: HIV, hematologic malignancies, solid tumors, AIDS-defining cancers, non-AIDS-defining cancers, antiretroviral therapy, immune dysfunction, CD4 T-cell count, viral oncogenesis, cancer survival, Characteristics, solid